The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Hospira Files Public Knowledge-Based Application for Generic Gemcitabine for Malignant Lymphoma
October 16, 2012
- Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
- Pirespa Debuts in South Korea through Ildong: Shionogi
October 15, 2012
- Long-Term Investments in Developing Countries Expects Returns from 2020: President Naito of Eisai
October 15, 2012
- Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
- Meiji Seika Pharma to Solely Market 3 Diagnostics for Infectious Diseases
October 12, 2012
- Hisamitsu Posts 4.0% Sales Increase in March-August by Market Share Recovery of Mohrus Tape Series
October 12, 2012
- Eisai to Dissolve, Absorb Its Diagnostics Research Subsidiary Palma Bee’Z
October 12, 2012
- AVEO Files NDA for Tivozanib in US: Astellas
October 12, 2012
- Ajinomoto, Astellas to Codevelop Nateglinide for Combination Use with DPP-4 Inhibitors
October 11, 2012
- MTPC, Kureha Fail to Meet Primary Goal in Global PIII Studies for Kremezin
October 11, 2012
- Kyorin to Transfer Pekiron to Galderma
October 11, 2012
- Sanofi Files Lawsuit against 3 Companies for Approved Allegra Generics
October 11, 2012
- Policy Directions Headed for “Price Cuts for Long-Listed Drugs,” “Price Control for High Priced Drugs”: Prof. Nakamura of Keio Univ.
October 11, 2012
- Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
- Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
- Daiichi Sankyo Espha Considers Manufacturing Generics to Be Listed in 2014 at Ranbaxy’s Factory
October 10, 2012
- Chugai Files Avastin for Ovarian Cancer
October 10, 2012
- Ethical Drug Sales Down 1.4% in August: Crecon Report
October 10, 2012
- Companies Voice Concern over Implementation of Bar Code Labeling Due to Few Design Companies
October 9, 2012
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…